Skip to main content

Skin in the game: comparing the private and public regulation of isotretinoin


This paper engages in a comparative-institutional analysis of the private and public risk-management programs of the drug isotretinoin, which are designed to prevent the undesired effects isotretinoin has on fetal development. This case study sheds light on the comparative effectiveness of private and public regulation in the pharmaceutical and healthcare markets. A range of evidence indicates that the private risk management program successful in reducing pregnancies and educating patients about the harmful effects isotretinoin can have on a fetus. These findings challenge a consensus found in the medical literature that the private program needed to be supplanted and contain implications for future risk-management policy in healthcare.

Corresponding author
Hide All
Abroms, L., Maibach, E., Lyon-Daniel, K., and Feldman, S. (2006), ‘What is the Best Approach to Reducing Birth Defects Associated with Isotretinoin?’, PLOS Medicine, 3 (11): 19781983.
Adams, J. and Lammer, E. (1991), Functional Neuroteratology of Short-Term Exposure to Drugs, Tokyo: Teikyo University Press.
Aguilar, S., Louis, C., Hicks, J., Zage, P., and Russell, H. (2014). ‘Congenital Neuroblastomain Aneonate with Isotretinoin Embryopathy’, Journal of Pediatric Hematology/Oncology, 36 (2): 7577.
American Academy of Dermatology (2015), ‘Isotretinoin: Treatment for Severe Acne’, [online] (accessed April 2016).
Arrow, K. (1963), ‘Uncertainty and the Welfare Economics of Medical Care’, American Economic Review, 53 (5): 941972.
Bloom, G., Standing, H., and Lloyd, R. (2008), ‘Markets, Information Asymmetry and Health Care: Toward New Social Contracts’, Social Science Medicine, 66 (10): 20762087.
Boettke, P. J. (2012), Living Economics Yesterday, Today, and Tomorrow, Oakland, CA: The Independent Institute.
Boettke, P. J. and Coyne, C. J. (2005), ‘Methodological Individualism, Spontaneous Order and the Research Program of the Workshop in Political Theory and Policy Analysis’, Journal of Economic Behavior and Organization, 57 (2): 145158.
Boettke, P. J., Coyne, C. J., and Leeson, P. T. (2013), ‘Comparative Historical Political Economy’, Journal of Institutional Economics, 9 (3): 285301.
Boettke, P. J., Palagashvili, L., and Lemke, J. (2013), ‘Riding in Cars with Boys: Elinor Ostrom's Adventures with the Police’, Journal of Institutional Economics, 9 (4): 407425.
Boodman, S. (2006), Too hard to take. The Washington Post, 2006 September 5. [online] (accessed July 2015).
Brinker, A., Kornegay, C., and Nourjah, P. (2005), ‘Trends in Adherence to a Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed Pregnancies’, Archives Journal of the American Academy of Dermatology, 141 (5): 563599.
Brinker, A., Trontell, A., and Beitz, A. (2002), ‘Pregnancy and Pregnancy Rates in Association with Isotretinoin (Accutane)’, Journal of the American Academy of Dermatology, 47 (5): 798–779.
Brown, S. and Connelly, L. B. (2005), ‘Market failure in long-term private health insurance markets: a proposed solution’, Applied Economic Letters, 12 (5): 281–284.
Center for Disease Control (2015), ‘2010 Pregnancy Rates Among US Women’, [online] (accessed May 2016).
Demsetz, H. (1969), ‘Information and Efficiency: Another Viewpoint’, Journal of Law and Economics, 12 (1): 122.
Dooren, C. (2006), ‘Accutane IPledge Program Requirements Leading to Illegal Online Sales’, [online] Wall Street Journal, 13 September. (accessed April 2014).
Doshi, A. (2007), ‘The Cost of Clear Skin: Balancing the Social and Safety Costs of IPledge with the Efficacy of Accutane (Isotretinoin)’, Seton Hall Law Review, 37 (2): 625660.
Eggleston, K. (2011), ‘Prescribing Institutions: Explaining the Evolution of Physician Dispensing’, Journal of Institutional Economics, 8 (2): 247270.
Food and Drug Administration (2007), ‘FDA Launches Web Page Warning Against Buying Accutane and its Generic Versions’, [online] (accessed April 2016).
Food and Drug Administration, n.d.a. Dermatologic and Ophthalmic Drugs Advisory Committee briefing document for NDA18-662 Accutane® (isotretinoin) capsules. [online] (accessed September 2015).
Food and Drug Administration, n.d.b. Estimating Accutane Use. [online] (accessed September 2015).
Food and Drug Administration, n.d.d. Isotretinoin update: iPLEDGE. [online] (accessed April 2016).
Food and Drug Administration, n.d.e. Dermatologic and Ophthalmic Drugs Advisory Committee Briefing Document for NDA 18–622 Accutane® (isotretinoin) Capsules (accessed March 2015).
Food and Drug Administration, n.d.e. Pregnancy Prevention Program: A Risk Management Program to Reduce Pregnancies During Accutane Treatment. [online] (accessed September 2015).
Forstner, M. Evaluation of the Effectiveness of Risk Management, Roche, Basel, Switzerland: PowerPoint Presentation.
Globerman, S., Hodges, H., and Vining, A. (2002). ‘Canadian and United States’ Health Care Systems Performance and Governance: Elements of Convergence’, Applied Health Economics Health Policy, 1 (2): 7588.
Goldsmith, L. A., Bolognia, J. L., Callen, J. P., Chen, S. C., Feldman, S. R., Lim, H. W., Lucky, A. W., Reed, B. R., Siegfried, E. C., Thiboutot, D. M., and Wheeland, R. G. (2004), ‘American Academy of Dermatology Consensus Conference on the Safe and Optimal Use of Isotretinoin: Summary and Recommendations’, Journal of the American Academy of Dermatology, 50 (60): 900906.
Gray, B. (1986), For-Profit Enterprise in Health Care, Washington, DC: National Academy Press.
Hoffman, J., Coffey, J., and Stubbings, J. (2010), ‘Practical Implementation of Risk Evaluations and Mitigation Strategies in Health Systems: The Experts Answer your Questions’, ASHP Advantage E-Newsletter. [online] (accessed September 2015).
Honein, M. A., Moore, C. A., and Erickson, J. D. (2004), ‘Can we Ensure the Safe use of known Human Teratogens? Introduction of Generic Isotretinoin in the US as an Example’, Drug Safety, 27 (14): 10691080.
Klein, D. and Tabarrok, A. (2004), ‘Who certifies off-label?’, Regulation, 27 (2): 6063.
Leeson, P. T. (2007), ‘Better off Stateless: Somalia Before and After Government Collapse’, Journal of Comparative Economics, 35 (4): 689710.
Leeson, P. T. (2011), ‘Government, Clubs, and Constitutions’, Journal of Behavior, & Organization, 80 (2): 301308.
Leeson, P. T. (2014a), ‘Pirates, Prisoners, and Preliterates: Anarchic Context and the Private Enforcement of Law’, European Journal of Law and Economics, 37 (3): 365379.
Leeson, P. T. (2014b), Anarchy Unbound why Self-Governance Works Better than you Think, Cambridge, MA: Cambridge University Press.
Leeson, P. T. and Coyne, C. J. (2012), ‘Sassywood’, Journal of Comparative Economics, 40 (4): 608620.
Leeson, P. T. and Boettke, P. J. (2009), ‘Two-Tiered Entrepreneurship and Economic Development’, International Review of Law and Economics, 29 (3): 252259.
Leibman, M. (2003), ‘Off-label, in Bounds’, Medical Marketing and Media. 1 December, Available. [online] (accessed September 2015).
Leiderman, D. (2009), ‘Risk Management of Drug Products and the U.S. Food and Drug Administration: Evolution and Context’, Drug and Alcohol Dependence, 105S (1): S9–S15.
Lipper, G. (2007), ‘Isotretinoin and iPLEDGE: Too Much Regulation or not Enough?’, Medscape Dermatology. 12 January [online] (accessed October 2015).
Lynk, W. J. (1995), ‘The Creation of Economic Efficiencies in Hospital Mergers’, Journal of Health Economics, 15 (5): 507530.
Main, E. (2009), ‘Prescription Acne Drug Pulled from Shelve’, Rodale News, 13 July. [online] (accessed April 2014).
Maloney, M., and Stone, S. (2011), ‘Isotretinoin and IPledge: A View of Results’, Journal of the American Academy of Dermatology, 65 (2): 418419.
McCormick, C. G., Henningfield, J. E., Haddox, J. D., Varguhese, S., Lindholm, A., Rosen, S., Wissel, J., Waxman, D., Carter, L. P., Seeger, V., and Johnson, R. E. (2009), ‘Case Histories in Pharmaceutical Risk Management’, Drug and Alcohol Independence, 105S (1): S42–S55.
Meadows, M. (2001). ‘The Power of Accutane’, FDA Consumer, 35 (2): 1923.
Medscape (2002), ‘Roche Initiates Enhanced Program to Prevent Accutane-Exposed Pregnancies’, Medscape Medical News. 22 February. [online] (accessed September 2015).
Mendelson, A., Governale, L., Trontell, A., and Seligman, P. (2005), ‘Changes in Isotretinoin Prescribing before and After Implementation of the System to Manage Accutane Related Teratogenicity (SMART) Risk Management Program’, Pharmacoepidemiology and Drug Safety, 14 (9): 615618.
Miller, H. (1998), ‘Failed FDA Reform’, Regulation, 21 (3): 2330.
Milne, R. and Torsney, B. (1997), ‘The Efficiency of Administrative Governance: The Experience of Pre-Reform British National Health Service’, Journal of Comparative Economics, 24 (2): 161180.
Mises, L. (1944), Bureaucracy, New Haven, CT: Yale University Press.
Mitchell, A., Van Bennekom, C., and Louik, C. (1995), ‘A Pregnancy Prevention Program in Women of Childbearing Age Receiving Isotretinoin’, New England Journal of Medicine, 333 (2): 101106.
Mobacken, H., Sundström, A., and Vahlquist, A. (2014), ‘30 Years with Isotretinoin “Miracle Medicine” Against Acne with Many Side Effects’, Lakartidningen, 111 (3–4): 9396.
Mosher, W. D. and Jones, J., (2010), ‘Use of Contraception in the United States: 1982–2008. National Center for Health Statistics’, [online] (accessed July 2016).
Mushkin, S. (1958), ‘Toward a Definition of Health Economists’, Public Health Reports, 73 (9): 785793.
Ostrom, E. (2005), Understanding Institutional Diversity, Princeton, NJ: Princeton University Press.
Ostrom, E. (2010), ‘Beyond Markets and States: Polycentric Governance of Complex Economic Systems’, American Economic Review, 100 (3): 133.
Pathak, D. and Escovitz, A. (1996), ‘Managed Competition and Pharmaceutical Care: An Answer to Market Failure’, Journal of Research In Pharmaceutical Economics, 7 (1–2): 16.
Peltzman, S. (1973), ‘An Evaluation of Consumer Protection Legislation: The 1962 Drug amendments’, Journal of Political Economy, 81 (5): 10491091.
Pinhero, S. P., Kang, E. M., Kim, C. Y., Governale, L. A., Zhou, E. H., and Hammad, T. A. (2013), ‘Concomitant use of Isotretinoin and Contraceptives Before and After iPledge in the United States’, Pharmacoepidemiology Drug Safety, 22 (12): 12511257.
Robertson, J., Polifka, J. E., Avner, M., Chambers, C., Delevan, G., Koren, G., Lavigne, S. V. S. V., Martinez, L. P., Martinez, L. P., Miller, R. K., and Carey, J. C. (2005), ‘A Survey of Pregnant Woman using Isotretinoin’, Birth Defects Research Part A: Clinical and Molecular, 73 (11): 881887.
Ruke, K. (2014), ‘Former FDA Staffer Claims Prescription Drug “Black Market” Going Unreported’, Mint Press News. 5 May. [online] (accessed May 2015).
Savedoff, W. (2004), ‘Kenneth Arrow and the Birth of Health Economics’, Bulletin of the World Health Organization, 82 (2): 139140.
Schonfeld, T. L., Amoura, N. J., and Kratochvil, C. J., (2009), ‘iPLEDGE Allegiance to the Pill: Evaluation of Year 1 of a Birth Defect Prevention and Monitoring System’, Journal of Law, Medicine, and Ethics, 37 (1): 104117.
Shin, J., Cheetham, T. C., Wong, L., Nui, F., Kass, E., Yoshinaga, M. A., Sorel, M., McCombs, J. S., and Sidney, S. (2011), ‘The Impact of the iPLEDGE Program on Isotretinoin Fetal Exposures in an Integrated Health Care System’, Journal of the American Academy of Dermatology, 65 (6): 11171125.
Smith, A. (1776 [1976]), An Inquiry into the Nature and Causes of the Wealth of Nations, Indianapolis, IN: Liberty Fund.
Smith, P. C., Stephan, A., Valdmanis, V., and Verheyen, P. (1997), ‘Principal-Agent Problems in Health Care Systems: An International Perspective’, Health Policy, 41 (1): 3760.
Stashhower, M. (2003), ‘Pregnancy Rates Associated with Isotretinoin (Accutane) and the FDA’, Journal of the American Academy of Dermatology, 49 (6): 12021203.
Stossel, T. (2015), Pharmaphobia: How the Conflict of Interest Myth Undermines American Medical Innovation, Lanham, MD: Rowman and Littlefield.
Stringham, E. P. (2015), Private Governance Creating Order in Economic and Social Life, New York, NY: Oxford University Press.
Tabarrok, A. (2000), ‘Assessing the FDA Via the Anomaly of Off-Label Drug Prescription’, The Independent Review, 5 (1): 2553.
Tullock, G. (1965). The Politics of Bureaucracy, New York City, NY: Public Affairs Press.
Uhl, K., Trontell, A., and Kennedy, D. (2007), ‘Risk Minimization Practices for Pregnancy Prevention: Understanding Risk, Selection Tools’, Pharmacoepidemiology and Drug Safety, 16 (3): 337348.
Walker, S. (2007), ‘Memorandum for Dermatologic and Ophthalmic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Members and Consultants’, [online] (accessed April 2016).
Ward, M. (1992), ‘Drug Approval Overregulation’, Regulation, 15 (2): 4753.
Werner, C. A., Papic, M. J., Ferris, L. K., and Schwarz, E. B. (2015), ‘Promoting safe use of isotretinoin by increasing contraceptive knowledge’, Journal of the American Medical Association: Dermatology, 151 (4): 389393.
Woodcock, J. (2002), ‘Concerns Regarding Accutane (Isotretinoin)’, [online] (accessed April 2016).
Wysowski, D. K., Swann, J., and Vega, A. (2002), ‘Use of Isotretinoin (Accutane) in the United States: Rapid Increase from 1992 Through 2000’, Journal of the American Academy of Dermatology, 46 (4): 505509.
Zomerdijk, I. M., Ruiter, R., Houweling, L. M. A., Herings, R. M. C., Sturkenboom, M. C. J. M, Strauss, S. M. J. M., and Stricker, B. H. (2014), ‘Isotretinoin Exposure During Pregnancy: A Population-Based Study in the Netherlands’, BJM Open, 4 (11): 17.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Journal of Institutional Economics
  • ISSN: 1744-1374
  • EISSN: 1744-1382
  • URL: /core/journals/journal-of-institutional-economics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed